Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Reply to: Lack of Diagnostic Utility of "Amino Acid Dysregulation Metabotypes".

Smith AM, Donley ELR, Burrier RE, King JJ, Amaral DG.

Biol Psychiatry. 2019 Apr 1;85(7):e43-e44. doi: 10.1016/j.biopsych.2018.11.013. Epub 2018 Dec 27. No abstract available.

PMID:
30595230
2.

Amino Acid Dysregulation Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism Spectrum Disorder.

Smith AM, King JJ, West PR, Ludwig MA, Donley ELR, Burrier RE, Amaral DG.

Biol Psychiatry. 2019 Feb 15;85(4):345-354. doi: 10.1016/j.biopsych.2018.08.016. Epub 2018 Sep 6.

3.

Biocon's target factory.

Neenan TX, Burrier RE, Kim S.

Nat Biotechnol. 2018 Sep 6;36(9):791-797. doi: 10.1038/nbt.4242. No abstract available.

PMID:
30188545
4.

A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues.

Palmer JA, Smith AM, Egnash LA, Colwell MR, Donley ELR, Kirchner FR, Burrier RE.

Reprod Toxicol. 2017 Oct;73:350-361. doi: 10.1016/j.reprotox.2017.07.011. Epub 2017 Jul 23.

PMID:
28746836
5.

Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children.

West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, Palmer JA, Fontaine BR, Conard KR, Corbett BA, Cezar GG, Donley EL, Burrier RE.

PLoS One. 2014 Nov 7;9(11):e112445. doi: 10.1371/journal.pone.0112445. eCollection 2014.

6.

Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening.

Palmer JA, Smith AM, Egnash LA, Conard KR, West PR, Burrier RE, Donley EL, Kirchner FR.

Birth Defects Res B Dev Reprod Toxicol. 2013 Aug;98(4):343-63. doi: 10.1002/bdrb.21078. Epub 2013 Oct 3.

PMID:
24123775
7.

The sodium-dependent ascorbic acid transporter family SLC23.

Bürzle M, Suzuki Y, Ackermann D, Miyazaki H, Maeda N, Clémençon B, Burrier R, Hediger MA.

Mol Aspects Med. 2013 Apr-Jun;34(2-3):436-54. doi: 10.1016/j.mam.2012.12.002. Review.

PMID:
23506882
8.

The ABCs of membrane transporters in health and disease (SLC series): introduction.

Hediger MA, Clémençon B, Burrier RE, Bruford EA.

Mol Aspects Med. 2013 Apr-Jun;34(2-3):95-107. doi: 10.1016/j.mam.2012.12.009. Review.

9.

A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing.

Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R, Daneshian M, Eskes C, Goldberg A, Hasiwa N, Hoffmann S, Jaworska J, Knudsen TB, Landsiedel R, Leist M, Locke P, Maxwell G, McKim J, McVey EA, Ouédraogo G, Patlewicz G, Pelkonen O, Roggen E, Rovida C, Ruhdel I, Schwarz M, Schepky A, Schoeters G, Skinner N, Trentz K, Turner M, Vanparys P, Yager J, Zurlo J, Hartung T.

ALTEX. 2012;29(1):3-91. doi: 10.14573/altex.2012.1.003.

PMID:
22307314
10.

Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.

Rouleau C, Roy A, St Martin T, Dufault MR, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher BA.

Mol Cancer Ther. 2006 Feb;5(2):219-29.

11.

Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.

Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB.

Biophys J. 2004 Jul;87(1):534-9.

13.

Wiedendiol-A inhibits cholesteryl ester binding to its transfer protein.

Wang S, Clemmons A, Chackalamannil S, Coval SJ, Sybertz E, Burrier R.

Zhongguo Yao Li Xue Bao. 1998 Sep;19(5):408-12.

14.

GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists.

Parker EM, Babij CK, Balasubramaniam A, Burrier RE, Guzzi M, Hamud F, Mukhopadhyay G, Rudinski MS, Tao Z, Tice M, Xia L, Mullins DE, Salisbury BG.

Eur J Pharmacol. 1998 May 15;349(1):97-105.

PMID:
9669502
15.

Genomic organization and functional characterization of the mouse GalR1 galanin receptor.

Wang S, He C, Maguire MT, Clemmons AL, Burrier RE, Guzzi MF, Strader CD, Parker EM, Bayne ML.

FEBS Lett. 1997 Jul 14;411(2-3):225-30.

16.

2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus.

Clader JW, Burnett DA, Caplen MA, Domalski MS, Dugar S, Vaccaro W, Sher R, Browne ME, Zhao H, Burrier RE, Salisbury B, Davis HR Jr.

J Med Chem. 1996 Sep 13;39(19):3684-93.

PMID:
8809157
17.

Inhibitors of acyl CoA:cholesterol acyltransferase.

Vaccaro W, Amore C, Berger J, Burrier R, Clader J, Davis H, Domalski M, Fevig T, Salisbury B, Sher R.

J Med Chem. 1996 Apr 12;39(8):1704-19.

PMID:
8648610
19.

Substituted (1,2-diarylethyl)amide acyl-CoA:cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity.

Clader JW, Berger JG, Burrier RE, Davis HR, Domalski M, Dugar S, Kogan TP, Salisbury B, Vaccaro W.

J Med Chem. 1995 May 12;38(10):1600-7.

PMID:
7752185
20.

Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.

Salisbury BG, Davis HR, Burrier RE, Burnett DA, Bowkow G, Caplen MA, Clemmons AL, Compton DS, Hoos LM, McGregor DG, et al.

Atherosclerosis. 1995 May;115(1):45-63.

PMID:
7669087
21.

The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine.

Burrier RE, Smith AA, McGregor DG, Hoos LM, Zilli DL, Davis HR Jr.

J Pharmacol Exp Ther. 1995 Jan;272(1):156-63.

PMID:
7815329
22.

2-Azetidinones as inhibitors of cholesterol absorption.

Burnett DA, Caplen MA, Davis HR Jr, Burrier RE, Clader JW.

J Med Chem. 1994 Jun 10;37(12):1733-6. No abstract available.

PMID:
8021912
23.

Demonstration of a direct effect on hepatic acyl CoA: cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster.

Burrier RE, Deren S, McGregor DG, Hoos LM, Smith AA, Davis HR Jr.

Biochem Pharmacol. 1994 Apr 29;47(9):1545-51.

PMID:
8185666
24.

Effects of acyl-CoA: cholesterol O-acyltransferase inhibition on cholesterol absorption and plasma lipoprotein composition in hamsters.

Schnitzer-Polokoff R, Compton D, Boykow G, Davis H, Burrier R.

Comp Biochem Physiol A Comp Physiol. 1991;99(4):665-70.

PMID:
1679704
25.
26.

Binding of acyl-CoA to liver fatty acid binding protein: effect on acyl-CoA synthesis.

Burrier RE, Manson CR, Brecher P.

Biochim Biophys Acta. 1987 Jun 23;919(3):221-30.

PMID:
3593745
27.

Binding of lysophosphatidylcholine to the rat liver fatty acid binding protein.

Burrier RE, Brecher P.

Biochim Biophys Acta. 1986 Nov 14;879(2):229-39.

PMID:
3768402
28.
29.

Supplemental Content

Loading ...
Support Center